Centessa Pharmaceuticals PLC Sponsored ADR $CNTA Shares Sold by Perceptive Advisors LLC

Perceptive Advisors LLC lessened its stake in Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) by 5.9% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 2,917,634 shares of the company’s stock after selling 183,268 shares during the quarter. Centessa Pharmaceuticals makes up approximately 1.3% of Perceptive Advisors LLC’s holdings, making the stock its 24th biggest holding. Perceptive Advisors LLC owned about 2.17% of Centessa Pharmaceuticals worth $72,970,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Eagle Health Investments LP bought a new stake in shares of Centessa Pharmaceuticals during the 3rd quarter valued at about $2,500,000. Foresite Capital Management VI LLC grew its position in shares of Centessa Pharmaceuticals by 4.8% during the 3rd quarter. Foresite Capital Management VI LLC now owns 1,314,019 shares of the company’s stock valued at $31,865,000 after buying an additional 60,640 shares during the last quarter. SG Americas Securities LLC grew its position in shares of Centessa Pharmaceuticals by 1,017.7% during the 4th quarter. SG Americas Securities LLC now owns 263,625 shares of the company’s stock valued at $6,593,000 after buying an additional 240,039 shares during the last quarter. Royce & Associates LP bought a new stake in shares of Centessa Pharmaceuticals during the 3rd quarter valued at about $5,999,000. Finally, Avoro Capital Advisors LLC grew its position in shares of Centessa Pharmaceuticals by 116.2% during the 3rd quarter. Avoro Capital Advisors LLC now owns 10,808,080 shares of the company’s stock valued at $262,096,000 after buying an additional 5,808,080 shares during the last quarter. Institutional investors own 82.01% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently weighed in on CNTA. Leerink Partners downgraded shares of Centessa Pharmaceuticals from an “outperform” rating to a “hold” rating and boosted their price objective for the company from $36.00 to $40.00 in a research report on Wednesday, April 1st. Wells Fargo & Company downgraded shares of Centessa Pharmaceuticals from an “overweight” rating to an “equal weight” rating and boosted their price objective for the company from $35.00 to $42.00 in a research report on Monday, April 20th. Lifesci Capital downgraded shares of Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, April 1st. Wolfe Research downgraded shares of Centessa Pharmaceuticals from an “outperform” rating to a “hold” rating in a research report on Tuesday, March 31st. Finally, Truist Financial downgraded shares of Centessa Pharmaceuticals from a “buy” rating to a “hold” rating and set a $38.00 price objective for the company. in a research report on Monday, April 13th. Four investment analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $41.33.

Insiders Place Their Bets

In related news, insider Karen M. Anderson sold 41,076 shares of the firm’s stock in a transaction that occurred on Thursday, March 26th. The shares were sold at an average price of $30.12, for a total transaction of $1,237,209.12. Following the completion of the sale, the insider directly owned 62,085 shares in the company, valued at approximately $1,870,000.20. This trade represents a 39.82% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 4.09% of the company’s stock.

Centessa Pharmaceuticals Trading Up 0.3%

Shares of NASDAQ:CNTA opened at $39.87 on Thursday. The company has a 50 day moving average of $39.65 and a 200-day moving average of $31.11. The firm has a market cap of $6.17 billion, a P/E ratio of -22.27 and a beta of 1.11. Centessa Pharmaceuticals PLC Sponsored ADR has a twelve month low of $12.30 and a twelve month high of $40.26. The company has a current ratio of 9.53, a quick ratio of 9.53 and a debt-to-equity ratio of 0.23.

Centessa Pharmaceuticals (NASDAQ:CNTA) last issued its quarterly earnings results on Tuesday, May 5th. The company reported ($0.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.14). As a group, analysts anticipate that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.65 earnings per share for the current fiscal year.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.